Fiche publication
Date publication
mai 2006
Journal
Lung cancer (Amsterdam, Netherlands)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Berghmans T, Mascaux C, Martin B, Ninane V, Sculier JP
Lien Pubmed
Résumé
Stage III NSCLC represents a heterogeneous group and the ISS remains unsatisfactory in term of prognosis prediction. The aim of the present study was to determine the role of TTF-1 as prognostic factor in stage III NSCLC in addition to other known clinical factors. All stage III NSCLC patients treated in our hospital were retrieved and searched for biopsy specimens. TTF-1 was assessed by immunohistochemistry (Novocastra SPT24). Between 01/1987 and 07/2003, 108 assessable stage III NSCLC patients were included in the study. Their principal characteristics were: median age 64 years (range 37-83), male/female 81/27, squamous/non squamous 52/56, IIIA/IIIB 44/64, median Karnofsky PS 80 (range 20-100). Forty-four patients were positive for TTF-1 (squamous 25.0% versus non-squamous 55.4%). In multivariate analysis, only three factors were statistically significantly associated with better survival: good PS, surgery and creatinine level.
Mots clés
Adult, Aged, Belgium, epidemiology, Biomarkers, Tumor, metabolism, Biopsy, Carcinoma, Non-Small-Cell Lung, metabolism, Female, Follow-Up Studies, Homeodomain Proteins, metabolism, Humans, Immunohistochemistry, Lung Neoplasms, metabolism, Male, Middle Aged, Nuclear Proteins, metabolism, Prognosis, Retrospective Studies, Survival Rate, Thyroid Nuclear Factor 1, Transcription Factors, metabolism
Référence
Lung Cancer. 2006 May;52(2):219-24
